Merrill maintains MedImmune at neutral

MedImmune Inc. was kept at a neutral rating by Merrill Lynch analyst Eric Ende as the company reported better-than-expected earnings per share and weak U.S. Synagis sales of $33 million. Merrill estimated Synagis sales of $43 million, while consensus expected $50 million. The analyst expects Synagis sales to remain weak through 2007 as new, more stringent Synagis guidelines are implemented. Shares of the Gaithersburg, Md.-based biotechnology company were down 84 cents, or 3.19%, at $25.46 on volume of 3,056,603 shares versus the three-month running average of 3,279,460 shares. (Nasdaq: MEDI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.